drugset / Trial / NCT07396324
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2026-12
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab and Tuvonralimab | Unknown | 5 mg/kg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |